Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. LUMO, a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market…#austin #lumospharma #pghd #phase2 #thisregistrationlink #pin #thiswebcastlink #investorsmedia
Source: Reuters: Health - Category: Consumer Health News Source Type: news